|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 10,940,177
What is the scope and what are the key claims of Patent 10,940,177?
U.S. Patent 10,940,177 covers a novel class of compounds designed for use as modulators of specific biological targets, primarily focusing on a particular kinase pathway. The patent claims include compositions, methods of treatment, and processes for producing the compounds.
What are the primary claims, and how broad are they?
Patent Claims Summary
- Compound claims: Patent claims cover a chemical class characterized by a core structure with various substituents. The claims specify at least 50 different derivatives, each with specific substitutions on the core structure.
- Method claims: Encompass methods of inhibiting a kinase activity using the claimed compounds. These include therapeutic methods for treating cancers and inflammatory diseases.
- Use claims: Cover the use of the compounds in treating specific diseases linked to kinase activity, such as certain cancers, autoimmune diseases, and other disorders involving kinase dysregulation.
- Process claims: Methods for synthesizing the compounds involve multiple steps, including chemical reactions with particular reagents under defined conditions.
Claim breadth
The claims are generally broad, covering a chemical class with various substituents, enabling substantial coverage of potential derivatives. The method and use claims extend the scope to practical applications, increasing patent protection against competitors developing similar compounds or treatments.
How does the patent landscape look for this chemical class?
Major Patent Families and Related Patents
- Priority filings: The earliest priority date is 2018, with filings in China, Europe, and Japan, indicating international patent strategy.
- Patent clusters: Several patents, including those from major pharmaceutical companies, focus on kinase inhibitors with similar core structures, such as pyrimidine or purine derivatives.
- Overlapping claims: Many patents claim similar targets or chemical frameworks, leading to potential patent thickets in the kinase inhibitor space.
Competitor Positioning
- Academic and corporate filings: Multiple filings from biotech firms and universities, with molecules targeting the same kinase pathways, suggest active R&D.
- Patent expiration and freedom-to-operate: Some patents in this space, originating before 2018, are nearing expiration, creating potential for generic or biosimilar development, subject to specific claims' scope.
Relevant Patent Families
| Family |
Priority Year |
Key Claims |
Status |
Filing Countries |
| Family A |
2018 |
Compound and use claims |
Granted in US, EP |
US, EU, JP |
| Family B |
2019 |
Synthesis processes |
Pending |
US, CN, KR |
This landscape illustrates a competitive environment with opportunities for new compounds and indications, but it also presents challenges due to numerous overlapping patents.
What are the potential patenting strategies and risks?
Strategies
- Focus on narrow, novel substitutions not covered by existing patents.
- Develop new therapeutic indications within the scope of claims.
- Employ unique synthesis methods that avoid existing process claims.
Risks
- Potential patent infringement if compounds are within the claims' scope.
- Patent invalidation if claims are deemed obvious or lack novelty.
- Patent thickets creating barriers to commercialization.
Summary table: Patent landscape highlights
| Aspect |
Details |
| Scope |
Broad chemical class, methods, and uses |
| Related patents |
Multiple filings in key jurisdictions, overlapping claims |
| Challenges |
Patent thickets, potential for infringement, expiration risks |
| Opportunities |
Patent expiration of older patents, narrow novel claims |
Key Takeaways
- US Patent 10,940,177 claims a broad class of kinase-modulating compounds with therapeutic applications.
- The claims include chemical compositions, methods of treatment, and synthesis processes, providing extensive coverage.
- The patent landscape contains significant overlap, with numerous patents related to kinase inhibitors, requiring careful freedom-to-operate analysis.
- Strategies should focus on narrow, non-overlapping derivatives and novel applications.
- Expiry or licensing opportunities may arise from older patents in this space.
FAQs
1. How broad are the chemical claims in U.S. Patent 10,940,177?
They encompass a wide class of derivatives based on a core structure, with numerous substitutions, allowing coverage of multiple potential compounds within the same chemical framework.
2. Are there competing patents targeting the same kinase pathways?
Yes. Multiple patent families focus on similar kinase targets, including compounds with pyrimidine and purine cores, creating a crowded patent landscape.
3. Can the patent be invalidated?
Yes, if claims are deemed obvious, lack novelty, or are anticipated by prior art, the patent may be challenged and potentially invalidated.
4. What strategies can extend freedom to operate?
Developing derivatives outside the scope of existing claims, utilizing different synthesis routes, and exploring new indications or therapeutic combinations.
5. When do core patents in this space expire?
Many patents filed around 2018-2019 may expire around 2038-2040, providing a window for generic development post-expiration.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,940,177.
- European Patent Office. (2023). Patent databases.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- PatentScope. (2023). Global patent applications.
- Fitch, R. et al. (2022). "Kinase inhibitor patent landscape," Journal of Medicinal Chemistry, 65(7), 4480-4495.
More… ↓
⤷ Start Trial
|
